News | June 30, 2023
Lupin achieves milestone for its phase 1 clinical stage MALT1 inhibitor program
Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully
Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully
Oncodesign Services and ImaginAb sign a Preclinical License and Supply Agreement
This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable
Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets
Investment enables development of revolutionary multi-omic platform using super-resolution imaging technology for earlier disease detection and accelerated discovery of therapeutics
The primary endpoint is to measure the change in liver stiffness measurement performed by transient elastography from Baseline to Week 52
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
Construction will begin this year with the new capacity anticipated by 2025
The superior Agilent 6495 Triple Quadrupole LC/MS (LC/TQ) System is ideal for demanding and challenging targeted analysis applications requiring the highest analytical sensitivity
Subscribe To Our Newsletter & Stay Updated
